TransMedics Group, Inc. (NASDAQ:TMDX - Get Free Report) shares gapped up prior to trading on Tuesday . The stock had previously closed at $64.05, but opened at $67.42. TransMedics Group shares last traded at $65.03, with a volume of 673,822 shares traded.
Analyst Ratings Changes
Several equities analysts recently issued reports on the stock. JPMorgan Chase & Co. reissued a "neutral" rating and set a $75.00 price target (down from $116.00) on shares of TransMedics Group in a report on Tuesday, December 17th. Needham & Company LLC reiterated a "hold" rating on shares of TransMedics Group in a research note on Wednesday, December 11th. Baird R W upgraded TransMedics Group to a "strong-buy" rating in a research report on Tuesday, September 24th. Robert W. Baird cut their price objective on TransMedics Group from $150.00 to $120.00 and set an "outperform" rating for the company in a research report on Wednesday, December 11th. Finally, Canaccord Genuity Group decreased their target price on TransMedics Group from $109.00 to $104.00 and set a "buy" rating on the stock in a report on Wednesday, November 20th. Three research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, TransMedics Group currently has an average rating of "Moderate Buy" and an average price target of $122.70.
View Our Latest Report on TMDX
TransMedics Group Trading Down 2.4 %
The company has a quick ratio of 7.33, a current ratio of 8.20 and a debt-to-equity ratio of 2.42. The company has a market cap of $2.10 billion, a P/E ratio of 66.53 and a beta of 2.12. The business has a 50-day moving average price of $73.56 and a two-hundred day moving average price of $120.20.
TransMedics Group (NASDAQ:TMDX - Get Free Report) last announced its quarterly earnings data on Monday, October 28th. The company reported $0.12 earnings per share for the quarter, missing the consensus estimate of $0.29 by ($0.17). TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The firm had revenue of $108.76 million for the quarter, compared to the consensus estimate of $115.00 million. During the same period in the prior year, the firm posted ($0.12) earnings per share. The business's revenue for the quarter was up 63.7% compared to the same quarter last year. On average, analysts predict that TransMedics Group, Inc. will post 1 EPS for the current year.
Insiders Place Their Bets
In other news, insider Tamer I. Khayal sold 1,084 shares of the company's stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $86.40, for a total value of $93,657.60. Following the completion of the sale, the insider now directly owns 20,843 shares of the company's stock, valued at $1,800,835.20. This represents a 4.94 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Edward M. Basile sold 6,750 shares of the stock in a transaction that occurred on Tuesday, November 5th. The shares were sold at an average price of $83.55, for a total transaction of $563,962.50. Following the completion of the sale, the director now owns 732 shares in the company, valued at $61,158.60. This represents a 90.22 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 7.00% of the company's stock.
Hedge Funds Weigh In On TransMedics Group
Several institutional investors and hedge funds have recently made changes to their positions in TMDX. Driehaus Capital Management LLC raised its position in shares of TransMedics Group by 15.8% during the second quarter. Driehaus Capital Management LLC now owns 1,486,073 shares of the company's stock worth $223,832,000 after purchasing an additional 202,867 shares during the period. Principal Financial Group Inc. raised its stake in shares of TransMedics Group by 260.1% in the 3rd quarter. Principal Financial Group Inc. now owns 202,287 shares of the company's stock valued at $31,759,000 after purchasing an additional 146,115 shares during the period. Hood River Capital Management LLC bought a new stake in shares of TransMedics Group in the second quarter valued at about $18,854,000. Canada Pension Plan Investment Board acquired a new position in shares of TransMedics Group during the second quarter worth about $16,086,000. Finally, Public Sector Pension Investment Board acquired a new position in shares of TransMedics Group during the third quarter worth about $11,079,000. Institutional investors and hedge funds own 99.67% of the company's stock.
About TransMedics Group
(
Get Free Report)
TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.
Featured Articles
Before you consider TransMedics Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TransMedics Group wasn't on the list.
While TransMedics Group currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.